Financing includes participation from new and existing investors
Strengthens balance sheet, with pro forma cash position of approximately $1.0 billion, extending expected financial runway into the.
Multiple preclinical and clinical abstracts accepted for presentation at 2024 ASCO Annual Meeting and AACR Annual Meeting underscore breadth of Bicycle® platform technology and pipeline
Continued.
Bicycle Therapeutics plc , a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide technology, today announced the acceptance.
Bicycle Therapeutics plc , a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide technology, today announced that management.